Hypercalcemia

Reading File

Now I'll search the medical library for hypercalcemia across multiple dimensions in parallel.

Finding Sources

Searching PubMed

"hypercalcemia"[MeSH Terms] AND management

Good results. Now let me read the most comprehensive sections - Goldman-Cecil (the main clinical medicine text) and Textbook of Family Medicine for the full hypercalcemia sections.

Reading File

Finding Sources

Excellent content. Let me continue reading the Goldman-Cecil section and get the clinical features/management sections.

Reading File

Excellent. Now let me get the treatment/management section from Goldman-Cecil and also fetch the PTH diagnostic diagram.

Reading File

Loading Image

I now have comprehensive content. Let me get the acute hypercalcemia treatment section.

Reading File

I now have very comprehensive content. Let me compile the full response.

Hypercalcemia

Definition and Severity Classification

Hypercalcemia is defined as a total serum calcium > 10.5 mg/dL (2.62 mmol/L) or ionized calcium > 5.25 mg/dL (1.31 mmol/L).

Grade	Total Serum Calcium
Mild	< 12 mg/dL (3.0 mmol/L)
Moderate	12-14 mg/dL (3.0-3.5 mmol/L)
Severe	> 14 mg/dL (3.5 mmol/L)

Prevalence is ~1-2% in the general population and 2-5% in hospitalized patients. - Goldman-Cecil Medicine, p. 1617

Pathophysiology

Hypercalcemia arises through three main mechanisms:

Increased bone resorption - the most common (e.g., osteoclast activation by PTH, PTHrP, or lytic metastases)
Increased GI calcium absorption - excess vitamin D or its analogues
Decreased renal calcium excretion - e.g., thiazide diuretics, familial hypocalciuric hypercalcemia (FHH)

PTH acts on osteoblasts to upregulate RANKL, stimulating osteoclast differentiation and activity, while inhibiting osteoprotegerin - net result is calcium liberation from bone into the extracellular fluid. - Goldman-Cecil Medicine

Causes (classified by PTH level)

HIGH PTH

Primary hyperparathyroidism (most common cause overall): solitary adenoma (~80%), hyperplasia (~15%), carcinoma (<1%), familial - MEN 1, MEN 2A, HPT-JT, FIHP
Tertiary hyperparathyroidism - hyperplasia in chronic renal failure

LOW PTH (suppressed)

Malignancy (most common cause of symptomatic hypercalcemia):

Humoral hypercalcemia of malignancy (HHM): PTHrP secretion by tumor (~80% of cancer-related cases) - carcinoma of lung, esophagus, renal cell, ovary, bladder
Local osteolytic hypercalcemia (LOH): multiple myeloma, breast carcinoma
1,25(OH)₂D production: lymphoma, germinoma
Ectopic PTH secretion (rare)

Excess Vitamin D:

Exogenous: vitamin D toxicity (supplements, cod liver oil)
Endogenous: granulomatous disorders (sarcoidosis, TB, histoplasmosis, coccidioidomycosis, leprosy, berylliosis), lymphoma

Drugs:

Thiazide diuretics, lithium, milk-alkali syndrome, vitamin A toxicity, total parenteral nutrition, estrogens/antiestrogens, aminophylline, foscarnet

Other endocrine disorders:

Thyrotoxicosis (mild, <12 mg/dL - responds to beta-blockers)
Pheochromocytoma, acute adrenal insufficiency, VIPoma

Immobilization (especially in Paget disease, prolonged bed rest)

ALTERED CALCIUM-SENSING RECEPTOR SET POINT

Familial Hypocalciuric Hypercalcemia (FHH) types 1-3 - autosomal dominant, asymptomatic, very low urinary calcium (calcium-to-creatinine clearance ratio <0.01); mutations in CaSR, G-protein alpha-11, or AP2S1

Primary hyperparathyroidism + malignancy account for nearly 90% of all cases. - Robbins Pathology, p. 1682

PTH-Based Diagnostic Differentiation

The intact PTH assay is the key first test in any hypercalcemia workup:

Intact PTH levels distinguishing primary hyperparathyroidism from hypercalcemia associated with malignancy

Figure: Intact PTH measurement in hypoparathyroidism, normals, primary hyperparathyroidism, and hypercalcemia of malignancy. - Schwartz's Principles of Surgery

In primary hyperparathyroidism, PTH is elevated or inappropriately normal. In malignancy-associated hypercalcemia, PTH is low to undetectable. PTHrP assay is useful for confirming humoral hypercalcemia of malignancy.

Clinical Features: "Bones, Stones, Moans, and Abdominal Groans"

System	Manifestations
Renal	Nephrolithiasis, nephrocalcinosis, polyuria, polydipsia (nephrogenic DI), renal insufficiency
Bone	Bone pain, fractures, osteitis fibrosa cystica, brown tumors (severe/chronic)
GI	Nausea, vomiting, constipation, anorexia, peptic ulcers, pancreatitis, gallstones
Neuromuscular	Weakness, fatigue, proximal muscle weakness, hyporeflexia
CNS/Psychiatric	Depression, lethargy, confusion, stupor, coma (in severe cases)
Cardiac	Shortened QT interval, aortic/mitral valve calcifications, hypertension

Symptoms tend to correlate with the rapidity of rise rather than absolute level alone. Calcium levels >14 mg/dL are often symptomatic regardless. - Goldman-Cecil Medicine; Textbook of Family Medicine

Diagnosis: Workup

Confirm true hypercalcemia - correct for albumin: corrected Ca = measured Ca + 0.8 × (4 - albumin g/dL); or measure ionized calcium directly
Intact PTH - first and most important test

Elevated/normal PTH → think primary hyperparathyroidism or FHH
Suppressed PTH → think malignancy, vitamin D toxicity, granulomatous disease

PTHrP if PTH suppressed and malignancy suspected
25-OH vitamin D and 1,25(OH)₂D - elevated 1,25(OH)₂D in granulomatous disorders and lymphoma
24-hour urinary calcium - low in FHH (Ca:Cr clearance ratio <0.01), high in primary hyperparathyroidism
Serum phosphorus - tends to be low in primary HPT (PTH effect)
Alkaline phosphatase, bone markers if bone disease suspected
Imaging: neck ultrasound and sestamibi scan for parathyroid adenoma localization before surgery; DEXA scan for bone density in PHPT

Biochemical profile in primary hyperparathyroidism (Table of Family Medicine): serum Ca ~10.7 mg/dL, PTH ~119 pg/mL (ref 10-65), serum phosphorus ~2.8 mg/dL, elevated urinary calcium.

Management

Acute/Severe Hypercalcemia (Ca >13.5-14 mg/dL or symptomatic)

Step 1 - Aggressive IV hydration:

Normal saline 2-4 L/day (first-line; expands volume, increases renal calcium excretion)
Furosemide (loop diuretic) can be added in patients at risk of fluid overload (NOT thiazides)

Step 2 - Bisphosphonates (mainstay for malignancy-associated):

IV zoledronic acid or pamidronate - inhibit osteoclast-mediated bone resorption
Onset 2-4 days; peak effect at 4-7 days

Step 3 - Calcitonin:

Salmon calcitonin 4 IU/kg SC/IM q12h - rapid onset (hours), but tachyphylaxis within 48-72h
Used as a bridge while bisphosphonates take effect

Step 4 - Denosumab:

Anti-RANKL monoclonal antibody - effective for bisphosphonate-refractory hypercalcemia
Note: Rebound hypercalcemia can occur after denosumab discontinuation (recent systematic review, PMID 41571922)

Step 5 - Glucocorticoids:

Useful for granulomatous disease (sarcoidosis) and vitamin D toxicity; reduce 1,25(OH)₂D production by activated macrophages
Prednisolone 40-60 mg/day

Step 6 - Dialysis - last resort in severe refractory cases or renal failure

For malignancy-related 1,25(OH)₂D excess (lymphoma): glucocorticoids and ketoconazole are effective in addition to standard measures. (See systematic review PMID 34581546 on this entity.)

Chronic Management / Primary Hyperparathyroidism

Parathyroidectomy is the only cure and is indicated if ANY of these criteria are met:

Any complication of PHPT (nephrolithiasis, osteitis fibrosa cystica)
Serum Ca >1 mg/dL above upper normal limit
Marked hypercalciuria (>400 mg/24h in men, >300 mg/24h in women) with increased stone risk
Creatinine clearance <60 mL/min
BMD T-score < -2.5 or vertebral fracture
Age <50 years
Episode of life-threatening hypercalcemia

Success rate ~98% by experienced surgeons. Bone mineral density improves over 6-10 years post-op with reduced fracture risk. - Goldman-Cecil Medicine, p. 1836

Watchful waiting (asymptomatic patients not meeting surgery criteria):

Annual serum Ca, PTH, 25-OH-D, eGFR, 24h urine Ca
DEXA every 1-2 years
Ensure adequate hydration; avoid thiazides and immobilization

Cinacalcet (calcimimetic):

Allosteric activator of the calcium-sensing receptor
Indicated when surgery is not feasible; reduces PTH and calcium
Dose: 30 mg once daily, titrated to max 180 mg/day
Also used for severe secondary hyperparathyroidism in dialysis patients

Special Entities

Familial Hypocalciuric Hypercalcemia (FHH)

Autosomal dominant, lifelong asymptomatic hypercalcemia
Key distinction from PHPT: Ca:Cr clearance ratio <0.01, hypermagnesemia, normal PTH in 80%
Genetic testing (CaSR, GNA11, AP2S1) is definitive
Parathyroidectomy is NOT beneficial; these patients are often misdiagnosed with PHPT

Milk-Alkali Syndrome

Caused by excessive calcium carbonate ingestion (antacids, supplements)
Triad: hypercalcemia, metabolic alkalosis, renal insufficiency

Hypercalcemia of Immobilization

Occurs with prolonged immobilization, especially in young patients and those with high bone turnover (Paget disease)
Treatment: mobilization, saline hydration, bisphosphonates if needed

Key Summary Points

Most common cause overall: Primary hyperparathyroidism
Most common cause of symptomatic/acute hypercalcemia: Malignancy
These two causes account for ~90% of cases
First test: Intact PTH
Acute treatment priority: IV saline hydration first, then IV bisphosphonates
Only cure for PHPT: Parathyroidectomy
Do not confuse with FHH - check urinary calcium and genetic testing

Sources: Goldman-Cecil Medicine 22E; Brenner & Rector's The Kidney; Robbins Pathology; Textbook of Family Medicine 9E; Schwartz's Principles of Surgery 11E

Want pdf

Reading File

Running Command

ls /home/daytona/workspace/ 2>/dev/null || mkdir -p /home/daytona/workspace

Running Command

mkdir -p /home/daytona/workspace/hypercalcemia && cat << 'PYEOF' > /home/daytona/workspace/hypercalcemia/generate_pdf.py from reportlab.lib.pagesizes import A4 from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.units import cm from reportlab.lib import colors from reportlab.platypus import SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, HRFlowable, KeepTogether from reportlab.lib.enums import TA_LEFT, TA_CENTER, TA_JUSTIFY output_path = "/home/daytona/workspace/hypercalcemia/Hypercalcemia.pdf" doc = SimpleDocTemplate( output_path, pagesize=A4, rightMargin=2*cm, leftMargin=2*cm, topMargin=2*cm, bottomMargin=2*cm, title="Hypercalcemia", author="Orris Medical" ) styles = getSampleStyleSheet() # Custom styles title_style = ParagraphStyle( 'CustomTitle', parent=styles['Title'], fontSize=22, textColor=colors.HexColor('#1a3a5c'), spaceAfter=6, fontName='Helvetica-Bold', alignment=TA_CENTER ) subtitle_style = ParagraphStyle( 'Subtitle', parent=styles['Normal'], fontSize=10, textColor=colors.HexColor('#555555'), spaceAfter=14, alignment=TA_CENTER ) h1_style = ParagraphStyle( 'H1', parent=styles['Heading1'], fontSize=13, textColor=colors.white, backColor=colors.HexColor('#1a3a5c'), spaceAfter=4, spaceBefore=10, leftIndent=-0.3*cm, rightIndent=-0.3*cm, fontName='Helvetica-Bold', leading=18, borderPad=4 ) h2_style = ParagraphStyle( 'H2', parent=styles['Heading2'], fontSize=11, textColor=colors.HexColor('#1a3a5c'), spaceAfter=3, spaceBefore=7, fontName='Helvetica-Bold', borderPadding=(0,0,2,0), ) h3_style = ParagraphStyle( 'H3', parent=styles['Heading3'], fontSize=10, textColor=colors.HexColor('#2e6da4'), spaceAfter=2, spaceBefore=5, fontName='Helvetica-Bold', ) body_style = ParagraphStyle( 'Body', parent=styles['Normal'], fontSize=9.5, leading=14, spaceAfter=5, alignment=TA_JUSTIFY, textColor=colors.HexColor('#222222') ) bullet_style = ParagraphStyle( 'Bullet', parent=body_style, leftIndent=14, bulletIndent=4, spaceAfter=2, ) note_style = ParagraphStyle( 'Note', parent=body_style, fontSize=8.5, textColor=colors.HexColor('#555555'), leftIndent=10, fontName='Helvetica-Oblique' ) def h1(text): return Paragraph(f" {text}", h1_style) def h2(text): return Paragraph(text, h2_style) def h3(text): return Paragraph(text, h3_style) def body(text): return Paragraph(text, body_style) def bullet(text, level=1): indent = 14 * level s = ParagraphStyle('b', parent=bullet_style, leftIndent=indent, bulletIndent=indent-10) return Paragraph(f"• {text}", s) def note(text): return Paragraph(text, note_style) def sp(h=4): return Spacer(1, h) def hr(): return HRFlowable(width="100%", thickness=0.5, color=colors.HexColor('#cccccc'), spaceAfter=4, spaceBefore=4) # TABLE STYLES def make_table(data, col_widths, header=True): t = Table(data, colWidths=col_widths, repeatRows=1 if header else 0) style = [ ('FONTNAME', (0,0), (-1,-1), 'Helvetica'), ('FONTSIZE', (0,0), (-1,-1), 9), ('VALIGN', (0,0), (-1,-1), 'MIDDLE'), ('GRID', (0,0), (-1,-1), 0.4, colors.HexColor('#cccccc')), ('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.white, colors.HexColor('#f5f8fc')]), ('TOPPADDING', (0,0), (-1,-1), 4), ('BOTTOMPADDING', (0,0), (-1,-1), 4), ('LEFTPADDING', (0,0), (-1,-1), 6), ('RIGHTPADDING', (0,0), (-1,-1), 6), ] if header: style += [ ('BACKGROUND', (0,0), (-1,0), colors.HexColor('#2e6da4')), ('TEXTCOLOR', (0,0), (-1,0), colors.white), ('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'), ] t.setStyle(TableStyle(style)) return t # ---- BUILD CONTENT ---- story = [] # Title story.append(Paragraph("HYPERCALCEMIA", title_style)) story.append(Paragraph("A Comprehensive Clinical Reference", subtitle_style)) story.append(hr()) story.append(sp(6)) # 1. Definition story.append(h1("1. DEFINITION & SEVERITY")) story.append(sp(4)) story.append(body("Hypercalcemia is defined as a total serum calcium >10.5 mg/dL (2.62 mmol/L) or ionized calcium >5.25 mg/dL (1.31 mmol/L). Prevalence is ~1–2% in the general population and 2–5% in hospitalized patients.")) story.append(sp(4)) sev_data = [ ["Grade", "Total Serum Calcium", "Clinical Relevance"], ["Mild", "< 12 mg/dL (< 3.0 mmol/L)", "Often asymptomatic; outpatient workup"], ["Moderate", "12–14 mg/dL (3.0–3.5 mmol/L)", "Symptoms likely; urgent treatment if symptomatic"], ["Severe", "> 14 mg/dL (> 3.5 mmol/L)", "Hypercalcemic crisis; requires immediate treatment"], ] story.append(make_table(sev_data, [3*cm, 6*cm, 7.5*cm])) story.append(sp(6)) # 2. Pathophysiology story.append(h1("2. PATHOPHYSIOLOGY")) story.append(sp(4)) story.append(body("Hypercalcemia arises through three mechanisms:")) story.append(bullet("Increased bone resorption — most common; PTH/PTHrP activates osteoclasts via RANKL upregulation on osteoblasts, inhibiting osteoprotegerin")) story.append(bullet("Increased GI calcium absorption — excess vitamin D or its analogues (1,25-OH₂D)")) story.append(bullet("Decreased renal calcium excretion — thiazide diuretics, familial hypocalciuric hypercalcemia (FHH)")) story.append(sp(4)) story.append(body("PTH acts on osteoblasts → RANKL upregulation → osteoclast activation → calcium liberation from bone into extracellular fluid.")) story.append(sp(6)) # 3. Causes story.append(h1("3. CAUSES (Classified by PTH Level)")) story.append(sp(4)) story.append(h2("A. High PTH")) story.append(bullet("Primary hyperparathyroidism — most common cause overall")) story.append(bullet("Solitary adenoma (~80%), hyperplasia (~15%), carcinoma (<1%)", level=2)) story.append(bullet("Familial: MEN 1, MEN 2A, HPT-JT, FIHP", level=2)) story.append(bullet("Tertiary hyperparathyroidism — autonomous hyperplasia in chronic renal failure")) story.append(sp(4)) story.append(h2("B. Low PTH (Suppressed) — Most common cause of symptomatic hypercalcemia")) story.append(h3("Malignancy (~80% of cancer-related cases via PTHrP):")) story.append(bullet("Humoral hypercalcemia of malignancy (HHM): PTHrP secretion — lung, esophagus, renal cell, ovary, bladder carcinoma")) story.append(bullet("Local osteolytic hypercalcemia (LOH): Multiple myeloma, breast carcinoma")) story.append(bullet("1,25(OH)₂D production: Lymphoma, germinoma")) story.append(bullet("Ectopic PTH secretion: Rare")) story.append(sp(3)) story.append(h3("Excess Vitamin D:")) story.append(bullet("Exogenous: vitamin D toxicity (supplements, cod liver oil)")) story.append(bullet("Endogenous (granulomatous): Sarcoidosis, TB, histoplasmosis, coccidioidomycosis, leprosy, berylliosis, HIV, lymphoma")) story.append(sp(3)) story.append(h3("Drugs:")) story.append(bullet("Thiazide diuretics, lithium, milk-alkali syndrome (calcium carbonate), vitamin A toxicity, TPN, estrogens/antiestrogens, aminophylline, foscarnet, denosumab (rebound on discontinuation)")) story.append(sp(3)) story.append(h3("Other Endocrine Disorders:")) story.append(bullet("Thyrotoxicosis (mild, <12 mg/dL; responds to beta-blockers), pheochromocytoma, acute adrenal insufficiency, VIPoma")) story.append(bullet("Immobilization (especially Paget disease, prolonged bed rest)")) story.append(sp(3)) story.append(h2("C. Altered Calcium-Sensing Receptor Set Point")) story.append(bullet("Familial Hypocalciuric Hypercalcemia (FHH) — autosomal dominant; types 1–3 (CaSR, GNA11, AP2S1 mutations); asymptomatic, Ca:Cr clearance ratio <0.01, normal/mild PTH elevation, hypermagnesemia")) story.append(sp(3)) story.append(note("Primary hyperparathyroidism + malignancy account for ~90% of all cases of hypercalcemia.")) story.append(sp(6)) # 4. Clinical Features story.append(h1("4. CLINICAL FEATURES")) story.append(sp(4)) story.append(body('"Bones, Stones, Moans, and Abdominal Groans" — the classic mnemonic for hypercalcemia symptoms:')) story.append(sp(4)) feat_data = [ ["System", "Manifestations"], ["Renal (Stones)", "Nephrolithiasis, nephrocalcinosis, polyuria, polydipsia (nephrogenic DI), renal insufficiency"], ["Bone (Bones)", "Bone pain, fractures, osteitis fibrosa cystica, brown tumors (severe/chronic PHPT)"], ["GI (Abdominal Groans)", "Nausea, vomiting, constipation, anorexia, peptic ulcers, pancreatitis, gallstones"], ["CNS/Psychiatric (Moans)", "Depression, lethargy, confusion, cognitive impairment, stupor, coma (severe)"], ["Neuromuscular", "Proximal muscle weakness, fatigue, hyporeflexia"], ["Cardiac", "Shortened QT interval on ECG, hypertension, valve calcifications (aortic/mitral)"], ] story.append(make_table(feat_data, [4.5*cm, 12*cm])) story.append(sp(4)) story.append(note("Symptom severity correlates with the rapidity of calcium rise as much as the absolute level. Levels >14 mg/dL are almost universally symptomatic.")) story.append(sp(6)) # 5. Diagnosis story.append(h1("5. DIAGNOSTIC WORKUP")) story.append(sp(4)) story.append(body("Step 1 – Confirm true hypercalcemia: Correct for albumin (corrected Ca = measured Ca + 0.8 × [4 − albumin g/dL]) or measure ionized calcium directly.")) story.append(sp(3)) story.append(body("Step 2 – Intact PTH (the single most important test):")) story.append(bullet("Elevated or inappropriately normal PTH → primary hyperparathyroidism or FHH")) story.append(bullet("Suppressed PTH → malignancy, vitamin D excess, granulomatous disease")) story.append(sp(3)) diag_data = [ ["Test", "When to Order", "Interpretation"], ["Intact PTH", "All cases — first test", "High = PHPT; Low = non-parathyroid cause"], ["PTHrP", "PTH suppressed, malignancy suspected", "Elevated in humoral hypercalcemia of malignancy"], ["25-OH Vitamin D", "All cases", "Elevated in vitamin D toxicity"], ["1,25(OH)₂D", "PTH low, PTHrP negative", "Elevated in granulomatous/lymphoma"], ["24h Urinary Calcium", "PTH elevated", "Low (<100 mg/day, CCR <0.01) suggests FHH"], ["Serum Phosphorus", "All cases", "Low in PHPT (PTH promotes phosphaturia)"], ["Alkaline Phosphatase", "Bone disease suspected", "Elevated with osteitis fibrosa cystica"], ["DEXA scan", "Confirmed PHPT", "T-score < −2.5 is a surgical indication"], ["Sestamibi / Neck US", "Before parathyroid surgery", "Localise adenoma"], ] story.append(make_table(diag_data, [4*cm, 5.5*cm, 7*cm])) story.append(sp(4)) story.append(h3("Biochemical Profile in Primary Hyperparathyroidism (typical):")) bio_data = [ ["Parameter", "Typical Value", "Reference Range"], ["Serum Calcium", "10.7 ± mg/dL", "8.2–10.2 mg/dL"], ["Serum Phosphorus", "2.8 ± 0.1 mg/dL", "2.5–4.5 mg/dL"], ["Alkaline Phosphatase", "114 ± 5 IU/L", "< 100 IU/L"], ["PTH (IRMA)", "119 ± 7 pg/mL", "10–65 pg/mL"], ["25-OH Vitamin D", "19 ± 1 ng/mL", "9–52 ng/mL"], ["Urinary Calcium", "240 ± 11 mg/g Cr", "Elevated"], ] story.append(make_table(bio_data, [5*cm, 5*cm, 6.5*cm])) story.append(sp(6)) # 6. Management story.append(h1("6. MANAGEMENT")) story.append(sp(4)) story.append(h2("A. Acute/Severe Hypercalcemia (Ca >13.5–14 mg/dL or symptomatic)")) story.append(sp(3)) mgmt_data = [ ["Agent / Measure", "Dose", "Mechanism", "Onset / Notes"], ["IV Normal Saline", "2–4 L/day", "Volume expansion → ↑ renal Ca excretion", "Hours; First-line always"], ["Furosemide", "20–40 mg IV prn", "Loop diuretic → calciuresis", "Use only after adequate hydration; prevents fluid overload"], ["Calcitonin (salmon)", "4 IU/kg SC/IM q12h", "Inhibits osteoclasts; ↑ renal Ca excretion", "Rapid onset (hours); tachyphylaxis in 48–72h — use as bridge"], ["Zoledronic acid", "4 mg IV over 15 min", "Bisphosphonate; inhibits osteoclast resorption", "Onset 2–4 days; peak 4–7 days; preferred for malignancy"], ["Pamidronate", "60–90 mg IV over 2–4h", "Bisphosphonate", "Alternative to zoledronic acid"], ["Denosumab", "120 mg SC q4wk", "Anti-RANKL monoclonal antibody", "Bisphosphonate-refractory cases; risk of rebound hypercalcemia on discontinuation"], ["Glucocorticoids", "Prednisolone 40–60 mg/day", "↓ 1,25(OH)₂D production (macrophages)", "Granulomatous disease, vitamin D toxicity, lymphoma"], ["Hemodialysis", "Urgent", "Removes calcium directly", "Last resort; severe refractory or renal failure"], ] story.append(make_table(mgmt_data, [3.5*cm, 3.5*cm, 4.5*cm, 5*cm])) story.append(sp(6)) story.append(h2("B. Primary Hyperparathyroidism — Surgical Indications (Any One Criterion)")) story.append(sp(3)) surg_data = [ ["Criterion", "Threshold"], ["Serum calcium", "> 1 mg/dL above upper limit of normal"], ["Creatinine clearance", "< 60 mL/min"], ["Bone mineral density (DEXA)", "T-score < −2.5 at any site OR vertebral fracture"], ["24h urinary calcium", "> 400 mg/day (men), > 300 mg/day (women) + increased stone risk"], ["Age", "< 50 years"], ["Complications", "Nephrolithiasis, nephrocalcinosis, osteitis fibrosa cystica"], ["History", "Episode of life-threatening hypercalcemia"], ] story.append(make_table(surg_data, [7*cm, 9.5*cm])) story.append(sp(3)) story.append(note("Parathyroidectomy achieves biochemical cure in ~98% of cases when performed by an experienced surgeon. BMD improves over 6–10 years post-operatively with reduced fracture risk. Adapted from Bilezikian JP et al., J Bone Miner Res 2022.")) story.append(sp(5)) story.append(h2("C. Medical Management (When Surgery Not Feasible / Watchful Waiting)")) story.append(bullet("Cinacalcet (calcimimetic): 30 mg once daily, titrated to max 180 mg/day. Allosteric activator of calcium-sensing receptor; reduces PTH and serum calcium. Also used for severe secondary hyperparathyroidism in dialysis patients.")) story.append(bullet("Bisphosphonates: Alendronate or risedronate — improve bone density in PHPT; do not consistently lower serum calcium")) story.append(bullet("Watchful waiting: Annual serum Ca, PTH, 25-OH-D, eGFR, 24h urine Ca; DEXA every 1–2 years; ensure adequate hydration; avoid thiazides")) story.append(sp(6)) # 7. Special Entities story.append(h1("7. SPECIAL ENTITIES")) story.append(sp(4)) story.append(h2("Familial Hypocalciuric Hypercalcemia (FHH)")) story.append(bullet("Autosomal dominant; lifelong asymptomatic hypercalcemia")) story.append(bullet("Key: Ca:Cr clearance ratio <0.01, hypermagnesemia, PTH normal in 80%")) story.append(bullet("3 subtypes: FHH1 (CaSR), FHH2 (GNA11), FHH3 (AP2S1) — genetic testing is definitive")) story.append(bullet("Parathyroidectomy is NOT beneficial — do not confuse with PHPT")) story.append(sp(3)) story.append(h2("Milk-Alkali Syndrome")) story.append(bullet("Caused by excessive calcium carbonate ingestion (antacids, OTC supplements)")) story.append(bullet("Classic triad: hypercalcemia + metabolic alkalosis + renal insufficiency")) story.append(sp(3)) story.append(h2("Hypercalcemia of Malignancy — Mechanism by Tumor Type")) malignancy_data = [ ["Tumor Type", "Mechanism"], ["Squamous cell lung, renal, ovarian, bladder", "PTHrP secretion (HHM) — ~80%"], ["Multiple myeloma, breast cancer", "Local osteolytic hypercalcemia (LOH) — cytokines, DKK1, RANKL"], ["Lymphoma (Hodgkin, NHL)", "1,25(OH)₂D production by tumor cells"], ["Rare solid tumors", "Ectopic PTH secretion"], ] story.append(make_table(malignancy_data, [7*cm, 9.5*cm])) story.append(sp(3)) story.append(h2("Hypercalcemia of Immobilization")) story.append(bullet("Occurs with prolonged immobilization, especially young patients and those with high bone turnover (Paget disease)")) story.append(bullet("Treatment: mobilization, IV saline hydration, bisphosphonates if needed")) story.append(sp(6)) # 8. Quick Reference story.append(h1("8. QUICK REFERENCE SUMMARY")) story.append(sp(4)) qr_data = [ ["Key Point", "Answer"], ["Most common cause overall", "Primary hyperparathyroidism (adenoma)"], ["Most common cause of symptomatic hypercalcemia", "Malignancy"], ["These two causes account for", "~90% of all cases"], ["First investigation", "Intact PTH"], ["First treatment (acute)", "IV Normal Saline (aggressive hydration)"], ["Fastest-acting pharmacological agent", "Calcitonin (onset hours; tachyphylaxis ≤72h)"], ["Best for malignancy-related hypercalcemia", "IV Bisphosphonate (zoledronic acid)"], ["Only cure for primary hyperparathyroidism", "Parathyroidectomy (~98% cure rate)"], ["Do NOT confuse PHPT with", "FHH — check urinary calcium + genetic testing"], ["Glucocorticoids useful for", "Granulomatous disease, vitamin D toxicity, lymphoma"], ] story.append(make_table(qr_data, [8*cm, 8.5*cm])) story.append(sp(8)) # Sources story.append(hr()) story.append(note("Sources: Goldman-Cecil Medicine 22E (2025); Brenner & Rector's The Kidney; Robbins & Cotran Pathologic Basis of Disease; Textbook of Family Medicine 9E; Schwartz's Principles of Surgery 11E; Harrison's Principles of Internal Medicine 22E")) story.append(sp(3)) story.append(note("Generated by Orris Medical AI — July 2026. For clinical decisions, verify with current institutional guidelines.")) doc.build(story) print(f"PDF saved: {output_path}") PYEOF python3 /home/daytona/workspace/hypercalcemia/generate_pdf.py

Your PDF is ready! Here's the download link:

Hypercalcemia

PDF Document · PDF

The PDF includes all sections from the previous response in a clean, structured format:

Definition & Severity Classification table
Pathophysiology
Full Causes by PTH level
Clinical Features table ("Bones, Stones, Moans, Groans")
Diagnostic Workup with investigation table + PHPT biochemical profile
Management tables (acute treatment with dosing, surgical indications, medical options)
Special entities (FHH, Milk-Alkali, Malignancy by tumor type)
Quick Reference Summary table

This is a shared conversation. Sign in to Orris to start your own chat.